Markus Zuber

6.6k total citations
100 papers, 4.0k citations indexed

About

Markus Zuber is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Markus Zuber has authored 100 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 44 papers in Surgery and 21 papers in Pathology and Forensic Medicine. Recurrent topics in Markus Zuber's work include Colorectal Cancer Surgical Treatments (26 papers), Breast Cancer Treatment Studies (18 papers) and Colorectal Cancer Treatments and Studies (16 papers). Markus Zuber is often cited by papers focused on Colorectal Cancer Surgical Treatments (26 papers), Breast Cancer Treatment Studies (18 papers) and Colorectal Cancer Treatments and Studies (16 papers). Markus Zuber collaborates with scholars based in Switzerland, Germany and United States. Markus Zuber's co-authors include Ulrich Güller, Daniel Oertli, J. Torhorst, Guido Sauter, Ossi R. Köchli, Holger Dieterich, Igor Langer, Frank Mross, F. Harder and Holger Moch and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Markus Zuber

98 papers receiving 3.8k citations

Peers

Countries citing papers authored by Markus Zuber

Since Specialization

Citations

This map shows the geographic impact of Markus Zuber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Zuber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Zuber more than expected).

Fields of papers citing papers by Markus Zuber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Zuber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Zuber. The network helps show where Markus Zuber may publish in the future.

Co-authorship network of co-authors of Markus Zuber

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Zuber. A scholar is included among the top collaborators of Markus Zuber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Zuber. Markus Zuber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neurogenic appendicopathy: A rare differential diagnosis of acute appendicitis 2023 ·Journal of Visceral Surgery ·(unknown), (unknown), (unknown), (unknown), Markus Zuber, René Fahrner	1
2	Outcome of open inguinal hernia repair using sutureless self-gripping mesh – a retrospective single cohort study 2021 ·Swiss Medical Weekly ·(unknown), (unknown), Dimitri A. Raptis, Lukas Eisner, Markus Zuber, Benjamin Weixler	1
3	Evaluation of the prognostic relevance of the recommended minimum number of lymph nodes in colorectal cancer—a propensity score analysis 2021 ·International Journal of Colorectal Disease ·Michaela Ramser, (unknown), René Warschkow, Carsten T. Viehl, Johannes C. Lauscher, Raoul A. Droeser, Christoph Kettelhack, Markus Zuber, Benjamin Weixler	4
4	Lymph node ratio is inferior to pN-stage in predicting outcome in colon cancer patients with high numbers of analyzed lymph nodes 2018 ·BMC Surgery ·Manuel O. Jakob, Ulrich Güller, (unknown), Daniel Oertli, Markus Zuber, Carsten T. Viehl	12
5	Is there a role for procalcitonin in differentiating uncomplicated and complicated diverticulitis in order to reduce antibiotic therapy? A prospective diagnostic cohort study 2017 ·Swiss Medical Weekly ·Victor Jeger, (unknown), (unknown), (unknown), Markus Zuber, Rein Jan Piso	16
6	Long-term Follow-up of a Randomized Controlled Trial of Lichtenstein's Operation Versus Mesh Plug Repair for Inguinal Hernia 2013 ·Annals of Surgery ·Raoul A. Droeser, Salome Dell‐Kuster, Anita Kurmann, Rachel Rosenthal, Markus Zuber, Jürg Metzger, Daniel Oertli, Christian Hamel, Daniel M. Frey	25
7	Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging? 2012 ·Langenbeck s Archives of Surgery ·(unknown), Tulin Cil, Ulrich Güller, Markus Zuber	6
8	Meeting the biologic challenge of colorectal metastases 2012 ·Clinical & Experimental Metastasis ·Harold J. Wanebo, Mark LeGolvan, Philip B. Paty, Sukamal Saha, Markus Zuber, Michael I. D’Angelica, N. E. Kemeny	40
9	Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial 2008 ·International Journal of Colorectal Disease ·U Laffer, U Metzger, P Aeberhard, Matthias Lorenz, F. Harder, Rudolf Maibach, Markus Zuber, R. Herrmann	15
10	Morbidity of Sentinel Lymph Node Biopsy (SLN) Alone Versus SLN and Completion Axillary Lymph Node Dissection After Breast Cancer Surgery 2007 ·Annals of Surgery ·Igor Langer, Ulrich Güller, Gilles Berclaz, Ossi R. Koechli, Gabriel Schaer, Mathias K. Fehr, Thomas Heß, Daniel Oertli, L. Bronz, (unknown), Edward Wight, (unknown), (unknown), Daniel Burger, Markus Zuber	285
11	Guideline zur Axilladissektion 2003 ·Schweizerische Ärztezeitung ·Markus Zuber, Daniel Oertli, (unknown), Thomas Köcher, (unknown), Gilles Berclaz, Ossi R. Köchli, F Harder, (unknown), (unknown), J. Benz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
12	Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome 2002 ·American Journal Of Pathology ·Matt van de Rijn, Charles M. Perou, Rob Tibshirani, (unknown), Olli Kallioniemi, Juha Kononen, J. Torhorst, Guido Sauter, Markus Zuber, Ossi R. Köchli, Frank Mross, Holger Dieterich, (unknown), D. T. Ross, David Botstein, Pat Brown	465
13	Disseminated Single Tumor Cells as Detected by Real-Time Quantitative Polymerase Chain Reaction Represent a Prognostic Factor in Patients Undergoing Surgery for Colorectal Cancer 2002 ·Annals of Surgery ·Ulrich Güller, Paul Zajac, Annelies Schnider, (unknown), (unknown), Markus Zuber, Giulio C. Spagnoli, Daniel Oertli, Robert Maurer, U Metzger, F Harder, Michael Heberer, (unknown)	134
14	Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints 2001 ·American Journal Of Pathology ·J. Torhorst, Christoph Bucher, Juha Kononen, Philippe Haas, Markus Zuber, Ossi R. Köchli, Frank Mross, Holger Dieterich, Holger Moch, Michael J. Mihatsch, Olli Kallioniemi, Guido Sauter	438
15	Endoscopic Surgery to the Axilla — A Substitute for Conventional Axillary Clearance? 1998 ·Recent results in cancer research ·F. Harder, Markus Zuber, Thomas Köcher, J. Torhorst	16
16	Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patients 1995 ·International Journal of Cancer ·Giulio C. Spagnoli, Christoph Schaefer, (unknown), Thomas Köcher, Antonio Amoroso, Antonio Juretić, Markus Zuber, (unknown), F. Harder, Michael Heberer	44
17	Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy 1994 ·Surgical Oncology ·Peter S. Goedegebuure, Markus Zuber, (unknown), (unknown), James C. Cusack, (unknown), (unknown), Timothy J. Eberlein	32
18	MAGE‐1 gene product is a cytoplasmic protein 1994 ·International Journal of Cancer ·Elke Schultz‐Thater, Antonio Juretić, Paolo Dellabona, (unknown), Walter Siegrist, F. Harder, Michael Heberer, Markus Zuber, Giulio C. Spagnoli	53
19	On the Relative Roles of Interleukin-2 and Interleukin-10 in the Generation of Lymphokine-Activated Killer Cell Activity 1993 ·Cellular Immunology ·Giulio C. Spagnoli, (unknown), Elke Schultz‐Thater, Paolo Dellabona, Luis Filgueira, Heidi Hörig, Markus Zuber, Gianni Garotta, Michael Heberer	31
20	PHARMACOKINETICS OF CYCLOSPORINE G IN PATIENTS WITH RENAL FAILURE 1988 ·Transplantation ·Markus R. Wenk, (unknown), Elı́sio Costa, Markus Zuber, S. Vožeh, G Thiel, E. Abisch, H. P. Keller, T. Beveridge, Ferenc Folláth	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact